The safety and tolerability of twice-daily oral doses of AZD5069, a novel CXCR2 antagonist, in patients with moderate-to-severe COPD
A.M. Kirsten, K. Förster, E. Radeczky, A. Linnhoff, B. Balint, H. Watz, H. Wray, L. Salkeld, M. Cullberg, H. Lam, B. Larsson (Grosshansdorf, Berlin, Germany; Százhalombatta, Deszk, Hungary; Mölndal, Södertälje, Sweden)
Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A.M. Kirsten, K. Förster, E. Radeczky, A. Linnhoff, B. Balint, H. Watz, H. Wray, L. Salkeld, M. Cullberg, H. Lam, B. Larsson (Grosshansdorf, Berlin, Germany; Százhalombatta, Deszk, Hungary; Mölndal, Södertälje, Sweden). The safety and tolerability of twice-daily oral doses of AZD5069, a novel CXCR2 antagonist, in patients with moderate-to-severe COPD. Eur Respir J 2012; 40: Suppl. 56, 3083
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Dose-ranging study to assess the efficacy and tolerability of NVA237, a once daily long-acting muscarinic antagonist, in patients with COPD Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008
Efficacy and tolerability of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients Source: Annual Congress 2007 - Mechanisms and new treatments of COPD Year: 2007
Tolerability and efficacy of inhaled AZD4818, a CCR1 antagonist, in moderate to severe COPD patients Source: Annual Congress 2009 - New drugs for airways disease Year: 2009
Comparison of efficacy and safety of twice-daily Glycopyrronium/Formoterol combination with once-daily Glycopyrronium in patients with moderate to severe COPD Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019
Safety and tolerability of NVA237, a once daily long-acting muscarinic antagonist, in patients with COPD Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008
Efficacy and safety of BI 671800, an oral CRTH2 antagonist, as add on therapy in poorly controlled asthma patients prescribed an inhaled corticosteroid Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012
Efficacy and safety of BI 671800, an oral CRTH2 antagonist, as add on therapy in poorly controlled asthma patients prescribed an inhaled corticosteroid Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012
Safety and tolerability of multiple-dose indacaterol, a novel 24-hour β2 -agonist, in patients with mild asthma Source: Eur Respir J 2005; 26: Suppl. 49, 253s Year: 2005
Efficacy and safety of aclidinium bromide, a novel long-acting muscarinic antagonist, in patients with moderate to severe COPD Source: Annual Congress 2009 - New bronchodilators Year: 2009
Efficacy and safety of BI 671800, an oral CRTH2 antagonist in controller naïve patients with poorly-controlled asthma Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012
NVA237, a once-daily inhaled anticholinergic, provides 24-hour bronchodilator efficacy in patients with moderate-to-severe COPD Source: Eur Respir J 2006; 28: Suppl. 50, 527s Year: 2006
Efficacy and safety of therapeutic and supratherapeutic doses of indacaterol compared to salmeterol and salbutamol, in mild-to-moderate asthma Source: Eur Respir J 2006; 28: Suppl. 50, 207s Year: 2006
Safety, tolerability and pharmacokinetics (PK) of repeated doses of GSK573719 inhalation powder, a new long-acting muscarinic antagonist, in healthy adults Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
Safety and tolerability of the novel very long acting β2-agonist Carmoterol given as a 2μg qd dose; 8 days comparison with formoterol and placebo in patients with persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 665s Year: 2006
Efficacy and safety of AZD3199, an inhaled ultra long-acting β2 -agonist, in patients with COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
Efficacy and safety of four doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i), in patients with moderate-to-severe COPD Source: International Congress 2019 – COPD clinical trials: new molecules and novel insights Year: 2019
Safety and efficacy of the inhaled pan-selectin antagonist bimosiamose in patients with COPD Source: Eur Respir J 2007; 30: Suppl. 51, 613s Year: 2007
Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study}, Source: Eur Respir J 2012; 40: 830-836 Year: 2012
Single-dose indacaterol, a novel 24-hour β2 -agonist, is well tolerated in patients with mild asthma Source: Eur Respir J 2005; 26: Suppl. 49, 253s Year: 2005
The efficacy and safety of long-acting muscarinic antagonist treatment for COPD Source: International Congress 2019 – Advances in chronic obstructive pulmonary disease and asthma Year: 2019